5/ And now @neerajaiims with a practice-informing trial for #Belzutifan in #RCC. More is not always better! The efficacy of belzutifan was similar between the 120 mg dose and the 200 mg dose for previously treated #ccRCC. @Annals_Oncology @myESMO htt…
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. https://t.co/gGqJLeCkx9
Happy @OncoAlert newsletter drop date to those who celebrate! 📰🎉 Featured in this newsletter is the recent @MDAndersonNews report on long-term outcomes of moderately hypofractionated preoperative RT for soft tissue sarcomas. Full paper here: https://t.c…